2269 — Meiji Holdings Share News
0.000.00%
Last trade - 00:00Table: Meiji HD -2022/23 group results
Table: Meiji HD -2022/23 parent results
Submitted New Drug Application To Manufacture And Market Arct-154, Next Generation Mrna Vaccine Against Covid-19, In Japan
Notice Concerning An Alliance Agreement For Distribution And Sales Of Arct-154, Next Generation Mrna Vaccine For Covid-19, In Japan
Brief: Marubeni Corp - To Acquire 100% Shares Of Meiji Sangyo Co, A Confectionery Manufacturer, From Meiji Co
Notice Concerning Cancellation Of Treasury Shares
Table: Meiji HD - 9-MTH group results
Notice Concerning Initiation Of Pediatric Phase III Clinical Trial Of KD-414, An Inactivated COVID-19 Vaccine
Brief: Meiji Holdings Co Ltd Says It Bought Back 888,300 Own Shares Worth 5.9 Billion Yen From Nov 29-Dec 23
Japan's Meiji Holdings says drug unit started late-stage trial for COVID vaccine
Notice Concerning Start Of Phase III Trial Of "Arct-154," A Potential New Class Of mRNA Vaccine For Covid-19, In Japan
Brief: Meiji Holdings Co Ltd Says It Bought Back 613,600 Own Shares Worth 4 Bln Yen From Nov 9-30
Brief: Meiji Holdings Co Ltd Says To Buy Back Up To 1.42% Of Own Shares Worth 10 Billion Yen
Table: Meiji HD - 6-MTH group results
Notice Concerning Adoption As "Developing Biopharmaceutical Manufacturing Sites To Strengthen Vaccine Production Project" Offered By Meti
Brief: Meiji Holdings: Subsidiary Meiji Seika Pharma In Talks With Arcturus Therapeutics Of The Us Regarding Manufacturing And Marketing Of Replicon Vaccine In Japan To Be Used For Covid Including Omicron Variant
Table: Meiji HD -Q1 group results
Japan's KM Biologics sees overseas demand for newly approved monkeypox vaccine
Notice Concerning Additional Approval In Japan For Freeze-Dried, Cell Culture-Derived Smallpox Vaccine Lc16 "Kmb" For Prevention Of Monkeypox